體外大腸直腸癌篩檢測試市場規模、佔有率、成長分析（按測試類型、最終用戶、按地區）- 產業預測，2025-2032 年

2023年外部大腸癌篩檢市場規模將為237.9億美元，預測期內（2025-2032年）複合年成長率為11.1%，從2024年的264.3億美元增至2032年的718億美元。將成長至8000萬美元。

由於大腸直腸癌病例的增加和創新基因檢測方法的引入，體外結直腸癌篩檢市場預計將顯著成長。這些測試包括各種有助於早期發現大腸直腸癌的微創篩檢選項，例如癒創木脂 FOB糞便檢驗、甲基化基因測定和大便潛血試驗。這些測試是使用先進的體外技術和成像系統進行的，使其適合在診所、醫院和診斷實驗室中使用。此外，消費者對使用 DNA 和遺傳生物標記進行先進測試的需求不斷增加，加上政府法規強制進行癌症篩檢，預計將在未來幾年推動這一市場領域的發展。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 抑制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 案例研究
• 技術評估
• 監管環境
• 管道分析
• 疾病流行病學

外部大腸癌篩檢測試市場規模：依測試類型

• 市場概況
• 大便潛血試驗
  • 癒創木脂 FOB糞便檢驗
  • 免疫Fob凝集試驗
  • 側流免疫FOB測試
  • 免疫福布 ELISA 測試
• 生物標記測試
  • 腫瘤M2-Pk糞便檢驗
  • 轉鐵蛋白測定
• CRC DNA篩檢測試
  • 甲基化基因檢測
• 小組 DNA 測試

外部大腸癌篩檢測試市場規模：按最終用戶分類

• 市場概況
• 醫院
• 診所
• 診斷實驗室
• 門診手術中心

體外大腸直腸癌篩檢測試市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2022-2024）

主要企業簡介

• Abbott Laboratories
• Beckman Coulter Inc
• Eiken Chemical Co., Ltd.
• Epigenomics
• Sysmex Corporation
• Siemens Healthcare GmbH
• Quest Diagnostics Incorporated
• OncoCyte Corporation
• Merck KGaA
• Immunostics Inc.
• Kyowa Kirin Co. Ltd.
• Randox Laboratories Ltd.
• R-Biopharm AG
• Bio-Rad Laboratories, Inc
• Exact Sciences Corporation
• F. Hoffmann-La Roche AG
• Genomic Health, Inc
• Hologic, Inc.
• Illumina, Inc.
• Invitae Corporation

結論和建議

In-Vitro Colorectal Cancer Screening Tests Market size was valued at USD 23.79 Billion in 2023 and is poised to grow from USD 26.43 Billion in 2024 to USD 71.88 Billion by 2032, growing at a CAGR of 11.1% during the forecast period (2025-2032).

The market for in-vitro colorectal cancer screening tests is poised for significant growth, driven by increasing incidences of colon and rectal cancers and the introduction of innovative genetic testing methods. These tests encompass a variety of screening options such as guaiac FOB stool tests, methylated gene assays, and faecal occult blood tests, which are minimally invasive and facilitate the early detection of colorectal cancer. They operate through advanced in-vitro techniques that utilize imaging systems, making them suitable for implementation in clinics, hospitals, and diagnostics laboratories. Moreover, supportive government regulations mandating cancer screenings, alongside heightened consumer demand for advanced tests leveraging DNA and genetic biomarkers, further bolster this market segment's expansion in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the In-Vitro Colorectal Cancer Screening Tests market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

In-Vitro Colorectal Cancer Screening Tests Market Segmental Analysis

Global In-Vitro Colorectal Cancer Screening Tests Market is segmented by test type, end user and region. Based on test type, the market is segmented into fecal occult blood tests, biomarker tests and CRC DNA screening tests. Based on end user, the market is segmented into hospitals, clinics, diagnostics laboratories and ambulatory surgical centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the In-Vitro Colorectal Cancer Screening Tests Market

The In-Vitro Colorectal Cancer Screening Tests market is experiencing notable growth driven by several key factors. The increasing incidence of colorectal cancer, influenced by an ageing population, unhealthy lifestyle choices, and rising diabetes rates, is propelling demand. Furthermore, heightened awareness of these screening tests, coupled with the widespread use of biomarkers, is contributing to market expansion. The desire for less invasive diagnostic methods and recent innovations in the field are expected to boost demand further. Additionally, awareness of the rising prevalence of colorectal cancer in younger populations and regulatory requirements for screening are also supporting market growth, allowing consumers to choose from various screening options tailored to individual needs.

Restraints in the In-Vitro Colorectal Cancer Screening Tests Market

The in-vitro colorectal cancer screening tests market may face several hindrances that could impede its growth. Key challenges include a shortage of skilled personnel and established screening protocols in developing countries, which limit effective implementation. Additionally, the insufficient reimbursement frameworks for in-vitro colorectal cancer testing further constrain market expansion. The Asia-Pacific region, in particular, is grappling with a significant deficit of qualified medical professionals, exacerbated by an aging population and increased physician workloads. Furthermore, the absence of supportive policies and initiatives aimed at raising awareness and encouraging the utilization of these tests may also hinder market development.

Market Trends of the In-Vitro Colorectal Cancer Screening Tests Market

The In-Vitro Colorectal Cancer Screening Tests market is witnessing significant growth driven by an alarming increase in colorectal cancer incidence among populations worldwide. Heightened public awareness surrounding the benefits of early detection and timely intervention further fuels this expansion. Technological advancements, particularly the integration of genetic testing into screening processes, are revolutionizing the market, facilitating not only early diagnosis but also the development of tailored treatment protocols. These innovations enhance the ability to curb the proliferation of cancerous cells, thereby reducing associated health risks. Collectively, these dynamics position the In-Vitro colorectal cancer screening segment for robust growth in the foreseeable future.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Technology Assessment
• Regulatory Landscape
• Pipeline Analysis
• Disease Epidemiology

Global In-Vitro Colorectal Cancer Screening Tests Market Size by Test Type & CAGR (2025-2032)

• Market Overview
• Fecal Occult Blood Tests
  • Guaiac Fob Stool Test
  • Immuno-Fob Agglutination Test
  • Lateral Flow Immuno-Fob Test
  • Immuno-Fob Elisa Test
• Biomarker Tests
  • Tumor M2-Pk Stool Test
  • Transferrin Assays
• CRC DNA Screening Tests
  • Methylated Gene Testing
• Panel DNA Tests

Global In-Vitro Colorectal Cancer Screening Tests Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Diagnostics Laboratories
• Ambulatory Surgical Centers

Global In-Vitro Colorectal Cancer Screening Tests Market Size & CAGR (2025-2032)

• North America (Test Type, End User)
  • US
  • Canada
• Europe (Test Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Test Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Test Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Test Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckman Coulter Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eiken Chemical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Epigenomics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthcare GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics Incorporated
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OncoCyte Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunostics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Kirin Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Randox Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• R-Biopharm AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genomic Health, Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invitae Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations